Impact of Iron-Deficiency Management on Quality of Life in Patients with Cancer: A Prospective Cohort Study (CAMARA Study). (4th March 2022)

• Record Type: Journal Article
• Authors: Gluszak, Cassandre; de Vries-Brilland, Manon; Seegers, Valérie; Baroin, Céline; Kieffer, Helene; Delva, Remy; Cornuault-Foubert, Delphine
• Is Part Of: Oncologist. Volume 27:Number 4(2022)
• Page Start: 328
• Page End: 333
• Publication Date: 2022-03-04
• Subjects: iron deficiency -- quality of life -- anemia -- supportive care -- cancer patients -- FACT-An scale; Oncology -- Periodicals; Tumors -- Periodicals; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Oncology; Tumors; Neoplasms; Electronic journals; Periodicals; Periodicals; 616.994
• DOI: 10.1093/oncolo/oyac005
• Languages: English
• ISSNs: 1083-7159

Abstract

Abstract: Background: Iron deficiency (ID) is very common in patients with solid tumors and may cause symptoms such as fatigue. However, its impact on clinical outcomes is poorly described. The aim of this prospective monocentric cohort study was to evaluate the evolution of quality of life (QoL) of these patients after iron supplementation. Methods: We included patients treated for a solid tumor, which were diagnosed with a functional (ferritin <800 ng/mL) or absolute (ferritin <300 ng/mL) ID (transferrin saturation coefficient <20%). The primary endpoint was patients' QoL evolution between baseline and intermediate visit, 15-30 days after initial intravenous iron supplementation, assessed by the Functional Assessment of Cancer Therapy-Anemia (FACT-An) scale. Secondary endpoints were the same assessment between baseline, intermediate, and final visit at 6 months and the evolution of functional capacities. Results: From 02/2014 to 12/2016, 248 patients were enrolled, of whom 186 were included in the analyses, including 140/186 (75.3%) with absolute ID. Anemia was detected in 141/174 (81.0%) patients at baseline. The FACT-An scores improved significantly between inclusion and intermediate visit ( P = .001) and also between the 3 times of evaluation ( P < .001). The most improved dimensions were those assessing physical, emotional well-being, and fatigue. Patients who performed the functional tests in all 3 phases had a significant improvement in performance on the majority of tests. Conclusion: The supplementation of ID was associated with an improvement of the QoL and functional capacities in patients with cancer. A randomized control trial is necessary to confirm our results. Our findings underline the importance of supportive care, including screening for ID, in oncology. Clinical trial registration number: NCT03625661. Abstract : Iron deficiency is common in patients with solid tumors and may cause fatigue. This article evaluates changes in the quality of life of these patients after iron supplementation.